GE HealthCare said it will acquire Sofie Biosciences for $945 million in cash, expanding its footprint in the U.S. radiopharmaceutical market. Sofie is a contract manufacturing organization that produces radioactive drugs for PET imaging, including F18-labeled products with a 110-minute half-life. That short window makes local production and rapid distribution essential, and Sofie's network of 15 U.S. sites is expected to help reduce bottlenecks in the adoption of these imaging agents.
The deal, expected to close in the first half of 2027, will fold Sofie into GE HealthCare's pharmaceutical diagnostics business, PDx. Sofie will continue to serve its existing customers as an independent manufacturing partner, while GE HealthCare gains U.S. rights to FAPI-74, a pan-cancer PET radiotracer it already holds rights to outside the U.S. Sofie currently manufactures GE HealthCare's Flyrcado F18 injection product.
GE HealthCare said the acquisition should contribute to revenue growth and adjusted earnings per share in the first full year of ownership. PDx CEO Kevin O'Neill said Sofie is expected to grow in the low double digits as part of GE HealthCare, allowing the company to participate across the radiopharmaceutical value stream through a mix of owned and partner facilities. The source reports no other details on financing or regulatory conditions beyond the expected closing timeline. Since only one source was provided, there are no conflicting accounts to compare.